Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :

IAVI Report: Mapping the Immunome

IAVI Report provides comprehensive scientific coverage of the AIDS vaccine field-from the latest scientific research, to policy, advocacy, and community perspectives, bringing news and analysis, adding context, and underscoring trends and gaps in the search for an AIDS vaccine. Read IAVI Report here  


Source Source: IAVI Report

CATIE: TreatmentUpdate 204: HIV and brain-related issues

TreatmentUpdate is CATIE's flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 204: August/September 2014 is available at:


Source Source: CATIE

J&J buys Alios for $1.75 billion

Johnson & Johnson has hit the acquisition trail and is buying viral disease expert Alios BioPharma for $1.75 billion in cash. The acquisition will include Alios’ portfolio of potential therapeutics for viral infections including AL-8176, an orally administered antiviral therapy currently in Phase II for the treatment of infants with respiratory syncytial virus (RSV)....


Source Source: PharmaTimes

PrEP will need high adherence, high effectiveness and high coverage in specific populations to be affordable in the US, New York study finds

A study based on New York City that modelled pre-exposure prophylaxis (PrEP) uptake there has found that in order to be affordable, PrEP would need to be tightly targeted at gay men at higher risk of HIV infection. Within this target population, it would need high levels of usage. A reduction in the price of Truvada – the tenofovir/emtricitabine combination pill...


Source Source: Aidsmap

Enanta regains full rights to NS5A inhibitor EDP-239 for hepatitis C virus from Novartis

WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 1, 2014-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the company has entered into an agreement to regain full rights from Novartis to EDP-239, an NS5A inhibitor currently in phase 1 development...